Premium Reports
Radiation Therapy 2019

Radiation Therapy 2019
Relationships a Key Driver of Value

Authored by: Monique Rasband and Lauren Barton June 6, 2019 | Read Time: 5  minutes

Current Time Inside Cache Tag Helper: 2/25/2021 11:29:20 PM and Model.reportId = 1545

The purchase of radiation therapy equipment is a large—and often long-term—investment, and while the vendors are few, the stakes are high. To be able to provide effective treatments and attract patients (who are more mobile and more involved in their care than ever), organizations need accurate, reliable technology backed by stellar vendor support. This report will help organizations determine which vendor will give them the best value by examining (1) customer loyalty and long-term plans; (2) relationships and support; and (3) ease of use and integration.

Healthcare Providers,
Want to see full details?

Not a Provider, contact us for pricing details.

Current Time Inside Cache Tag Helper: 2/25/2021 11:29:20 PM and Model.reportId = 1545

Key Findings

  1. Customers Consistently Derive Value with Elekta and Varian
  2. 25% of Accuray Customers Don't See Value, Driving Lowest Industry Loyalty
  3. Varian Relationships Continue to Improve, Earning the Vendor a Second Change with Former Customers
  4. Newer TomoTherapy Versions See Less Downtime; Accuray Field Support Still Spread Thin
  5. Varian Customers Satisfied with Integration; Accuray Customers Isolated by Siloed Treatment Planning
  6. Philips' Treatment Planning Weaker for Integration, Weakest When Paired with Varian Equipment
 Download Report Brief  Download Full Report

This material is copyrighted. Any organization gaining unauthorized access to this report will be liable to compensate KLAS for the full retail price. Please see the KLAS DATA USE POLICY for information regarding use of this report. © 2021 KLAS Research, LLC. All Rights Reserved. NOTE: Performance scores may change significantly when including newly interviewed provider organizations, especially when added to a smaller sample size like in emerging markets with a small number of live clients. The findings presented are not meant to be conclusive data for an entire client base.